Personalized Medicine Market Size, Share & Trends Analysis growing at a CAGR of 8.80% from 2025 to 2033
The global personalized medicine market size was estimated at USD 567.10 billion in 2024 and is projected to reach USD 1,196.18 billion by 2033, growing at a CAGR of 8.80% from 2025 to 2033. The growing demand for targeted therapies and precision diagnostics is significantly driving the expansion of the personalized medicine market.
Key Market Trends & Insights
- North America personalized medicine market held the largest share of 40.17% of the global market in 2024.
- The personalized medicine industry in the U.S. is expected to grow significantly over the forecast period.
- By product, the personalized nutrition & wellness segment held the highest market share of 32.0% in 2024.
- By end use, the hospitals segment held the highest market share in 2024.
Market Size & Forecast
- 2024 Market Size: USD 567.10 Billion
- 2033 Projected Market Size: USD 1,196.18 Billion
- CAGR (2025-2033): 8.80%
- North America: Largest market in 2024
- Asia Pacific: Fastest growing market
Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/personalized-medicine-market/request/rs1
Advances in genomic technologies, biomarker identification, and data-driven treatment strategies enable healthcare providers to tailor therapies to individual patient profiles. This approach enhances treatment efficacy, minimizes adverse effects, and supports more efficient use of healthcare resources. As chronic and complex diseases rise globally, the focus on personalized solutions continues to strengthen, fostering innovation and investment across diagnostics, therapeutics, and health data integration platforms. The rise in chronic conditions such as cancer, diabetes, and cardiovascular diseases is prompting healthcare providers to implement individualized treatment strategies.
Personalized diagnostics deliver greater accuracy in disease identification, leading to earlier intervention and better clinical outcomes. Personalized diagnostics delivered greater accuracy in disease identification, as in 2024 when Illumina’s FDA‑approved TruSight Oncology Comprehensive test analyzed over 500 genes to guide targeted cancer treatments. The increasing awareness among patients of genetic predispositions supports the uptake of DNA-based testing services. This movement toward proactive, patient-specific care models continues to expand the market’s potential across medical domains.
Technological advancements in genomics, artificial intelligence, and data analytics further fuel growth in the personalized medicine market. Companies are leveraging next-generation sequencing, biomarker discovery, and bioinformatics to develop innovative solutions tailored to individual patient profiles. AI integration into clinical decision-making is enabling faster analysis of complex datasets, enhancing diagnostic precision and therapy selection. Telemedicine platforms and health IT systems facilitate remote access to personalized care, especially in chronic disease management. These technological innovations are reshaping healthcare delivery and supporting the scalable adoption of customized approaches.
Increasing private sector investments and strategic collaborations are also contributing to market momentum. Pharmaceutical companies are partnering with diagnostics firms to co-develop companion diagnostics for targeted therapies. Startups and biotech firms are entering the market with innovative nutrition, wellness, and genomics offerings. Expanding consumer interest in health optimization and preventive care is boosting demand for direct-to-consumer testing and customized wellness plans. Market players focus on product differentiation, data-driven strategies, and global expansion to strengthen their competitive positions.
